利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.03 秒)

    INTERLACED METHOD FOR TREATING CANCER OR A PRECANCEROUS CONDITION
    5.
    发明申请
    INTERLACED METHOD FOR TREATING CANCER OR A PRECANCEROUS CONDITION 审中-公开
    用于治疗癌症或预防性病症的相互联系的方法

    公开(公告)号：US20120088807A1

    公开(公告)日：2012-04-12

    申请号：US13375846

    申请日：2010-06-04

    申请人： Andrew J. Krouse ,  Lloyd S. Gray ,  Timothy MacDonald ,  Joel Linden

    发明人： Andrew J. Krouse ,  Lloyd S. Gray ,  Timothy MacDonald ,  Joel Linden

    IPC分类号： A61K31/4188 ,  A61P35/00

    CPC分类号： A61K31/70 ,  A61K31/4184 ,  A61K31/66 ,  A61K33/24 ,  A61K38/14 ,  A61K2300/00

    摘要： The present invention provides a method for treating a disease or condition in a mammal which comprises the steps of; administering a therapeutically effective amount of a T type calcium channel inhibitor to effectively slow or stop progression of eukaryotic cells through the S, G2 and M phases of the cell cycle to increase the proportion of the eukaryotic cells in the G1 phase, stopping administration of the T type calcium channel inhibitor for a period of time, and administering a dosage selected from the group consisting of a dosage of at least one chemotherapeutic agent, a dosage of radiation, and combinations thereof, to kill the proportion of eukaryotic cells progressing past the G1 phase of the cell cycle after the stopping of the administration of the T type calcium channel inhibitor.

    摘要翻译： 本发明提供一种治疗哺乳动物疾病或病症的方法，其包括以下步骤： 施用治疗有效量的T型钙通道抑制剂以有效地减缓或停止通过细胞周期的S，G2和M期进行真核细胞的进展，以增加G1期中真核细胞的比例，停止施用 T型钙通道抑制剂持续一段时间，并施用选自剂量的至少一种化学治疗剂，剂量的辐射剂及其组合的剂量，以杀死通过G1进行的真核细胞的比例 在停止施用T型钙通道抑制剂后，细胞周期的相位。

    Generator with ferromagnetic teeth
    7.
    发明授权
    Generator with ferromagnetic teeth 有权
    发电机铁磁齿

    公开(公告)号：US08319390B2

    公开(公告)日：2012-11-27

    申请号：US13164023

    申请日：2011-06-20

    申请人： Gregory L. Snitchler ,  Timothy MacDonald

    发明人： Gregory L. Snitchler ,  Timothy MacDonald

    IPC分类号： H02K3/04

    CPC分类号： H02K1/165 ,  H02K7/1838 ,  H02K55/04 ,  H02K2213/03 ,  Y02E10/725 ,  Y02E40/625

    摘要： A stator assembly for use in a superconducting generator operated at frequencies up to 10 Hz is disclosed. The stator assembly includes a ferromagnetic stator winding support having a plurality of teeth defining slots, the slots configured to receive and support stator windings. The stator winding support is formed so that the ratio of the sum of the widths of the slots to the sum of the widths of the teeth and slots is in the range of 0.65 to 0.90.

    摘要翻译： 公开了用于在高达10Hz的频率下运行的超导发电机的定子组件。 定子组件包括铁磁定子绕组支撑件，其具有限定槽的多个齿，所述槽配置成接收和支撑定子绕组。 定子绕组支撑件形成为使得槽的宽度之和与齿和槽的宽度之和的比率在0.65至0.90的范围内。

    Method for determination of the amount of either phosphotyrosine or phosphoserine in a protein
    8.
    发明授权
    Method for determination of the amount of either phosphotyrosine or phosphoserine in a protein 失效
    测定蛋白质中磷酸酪氨酸或磷酸丝氨酸量的方法

    公开(公告)号：US5686310A

    公开(公告)日：1997-11-11

    申请号：US467717

    申请日：1995-06-06

    申请人： Timothy A.J. Haystead ,  Timothy MacDonald ,  R. Patrick Fadden

    发明人： Timothy A.J. Haystead ,  Timothy MacDonald ,  R. Patrick Fadden

    IPC分类号： C07K1/00 ,  C07K1/107 ,  C07K1/13

    CPC分类号： C07K1/003 ,  C07K1/1077 ,  Y10T436/16

    摘要： Traditional methods for measuring the phosphorylation state of cellular proteins have relied on .sup.32 P-orthophosphate labeling of cells in culture. The problems associated with radioactive isotopes have therefor prohibited phosphorylation studies on whole animals and humans. The present invention provides a unique technique that allows quantitative attachment of probes (e.g. fluorophors or biotin) to phospho-proteins and peptides by activating phospho-amino acids. the phosphorylation state of cellular proteins derived from human tissues can now be measured. This method can be used for early detection of cancer and diabetes and also for the identification of pharmaceutical agents.

    摘要翻译： 用于测量细胞蛋白磷酸化状态的传统方法依赖于32P-正磷酸盐对培养细胞的标记。 与放射性同位素相关的问题因此禁止对整个动物和人类进行磷酸化研究。 本发明提供了一种独特的技术，其允许通过激活磷酸 - 氨基酸使探针（例如荧光体或生物素）与磷酸蛋白质和肽的定量连接。 现在可以测量源于人组织的细胞蛋白的磷酸化状态。 该方法可用于癌症和糖尿病的早期检测，也可用于鉴定药剂。

    GENERATOR WITH FERROMAGNETIC TEETH
    9.
    发明申请
    GENERATOR WITH FERROMAGNETIC TEETH 有权
    发电机与非磁性材料

    公开(公告)号：US20110248509A1

    公开(公告)日：2011-10-13

    申请号：US13164023

    申请日：2011-06-20

    申请人： Gregory L. Snitchler ,  Timothy MacDonald

    发明人： Gregory L. Snitchler ,  Timothy MacDonald

    IPC分类号： F03D9/00 ,  H02K1/16

    CPC分类号： H02K1/165 ,  H02K7/1838 ,  H02K55/04 ,  H02K2213/03 ,  Y02E10/725 ,  Y02E40/625

    摘要： A stator assembly for use in a superconducting generator operated at frequencies up to 10 Hz is disclosed. The stator assembly includes a ferromagnetic stator winding support having a plurality of teeth defining slots, the slots configured to receive and support stator windings. The stator winding support is formed so that the ratio of the sum of the widths of the slots to the sum of the widths of the teeth and slots is in the range of 0.65 to 0.90.

    摘要翻译： 公开了用于在高达10Hz的频率下运行的超导发电机的定子组件。 定子组件包括铁磁定子绕组支撑件，其具有限定槽的多个齿，所述槽配置成接收和支撑定子绕组。 定子绕组支撑件形成为使得槽的宽度之和与齿和槽的宽度之和的比率在0.65至0.90的范围内。

    Gamma-glutamyl transpeptidase-specific antibody, prodrugs for the treatment of gamma-glutamyl transpeptidase-expressing tumors, and methods of administration thereof
    10.
    发明授权
    Gamma-glutamyl transpeptidase-specific antibody, prodrugs for the treatment of gamma-glutamyl transpeptidase-expressing tumors, and methods of administration thereof 失效
    γ-谷氨酰转肽酶特异性抗体，用于治疗表达γ-谷氨酰转肽酶的肿瘤的前药及其施用方法

    公开(公告)号：US5854006A

    公开(公告)日：1998-12-29

    申请号：US825349

    申请日：1997-03-28

    申请人： Marie Hanigan ,  Timothy MacDonald

    发明人： Marie Hanigan ,  Timothy MacDonald

    IPC分类号： C07K16/40 ,  C12N9/10 ,  G01N33/573 ,  G01N33/53 ,  C07K16/00

    CPC分类号： C12N9/104 ,  C07K16/40 ,  G01N33/573

    摘要： An antibody is provided which binds to active GGT, and can identify tissues which express GGT on their surface. Many solid tumors express GGT on their surface. Individuals identified with such tumors may be treated with inactivated prodrugs of chemotherapeutic agents at local dosage levels substantially above the maximum dosage levels currently permitted due to side effect limitations. The prodrugs are comprised of chemotherapeutic agents rendered inactive by the attachment of a gamma-glutamyl group thereto. The gamma-glutamyl group is cleaved by GGT on the surface of solid tumor cells expressing GGT, and thus active only locally against the tumor. Side effects are suppressed. The antibody is used to identify solid tumors that are candidates for this treatment, as well as to identify tissues which express GGT and which must therefore be the basis of selection criteria of various available chemotherapeutic agents.

    摘要翻译： 提供与活性GGT结合的抗体，并且可以鉴定表达GGT的组织。 许多实体瘤在其表面表达GGT。 用这些肿瘤鉴定的个体可以用局部剂量水平的化学治疗剂的灭活前药进行治疗，其实质上高于由于副作用限制而允许的最大剂量水平。 前药由通过连接γ-谷氨酰基而变得无活性的化学治疗剂组成。 γ-谷氨酰基在表达GGT的实体肿瘤细胞表面被GGT切割，因此仅在局部对抗肿瘤。 副作用被抑制。 该抗体用于鉴定作为该治疗的候选物的实体瘤，以及鉴定表达GGT的组织，因此必须是各种可用的化学治疗剂的选择标准的基础。